Scrutiny is mounting on Swiss federal financial planning. Auditors have slammed multi-billion franc underestimations in railway upgrade costs, while the long-awaited publication of unredacted Covid vaccine contracts reveals the high price of securing early access.

"The secrecy surrounding the FOPH has finally come to an end."
Switzerland’s reputation for clockwork precision is under fire as a staggering multi-billion franc hole emerges in federal rail planning. The Swiss Federal Audit Office (SFAO) has slammed the Federal Office of Transport for 'wildly' underestimating the costs of major railway upgrades, citing a catastrophic failure in data quality and financial forecasting. These aren't mere rounding errors; we are talking about a systemic lack of transparency that leaves Parliament flying blind on the nation’s most critical infrastructure projects. The SFAO report exposes a culture of incomplete data where VAT and inflation are frequently ignored, creating a fictional financial landscape. As the Rail Infrastructure Fund (RIF) grapples with these discrepancies, the government confronts a grim reality: the projects promised to the public may cost billions more than admitted. This financial negligence threatens to derail the very mobility that keeps the Swiss economy humming.
The veil of secrecy has finally been torn away from Switzerland’s pandemic spending, revealing a 'premium' price tag for early vaccine access. Following a landmark court victory for transparency, unredacted contracts show Switzerland paid a staggering $32 to $35 per dose to Moderna—nearly double what the United States paid for the same product. While the Federal Office of Public Health (FOPH) fought for two years to keep these figures hidden, claiming disclosure would harm national interests, the courts disagreed. The newly public documents reveal that Bern funneled nearly $1 billion to Moderna and Novavax alone. This 'priority supply' list came with a heavy cost: Switzerland agreed to shoulder almost all liability for rare side effects, shielding pharmaceutical giants from nearly all risk. It is a sobering look at the desperate leverage held by big pharma during a global crisis.
Efficiency has been replaced by excess as data confirms Switzerland destroyed a shocking 18.6 million doses of expired Covid-19 vaccines. That represents a staggering 60% of all doses purchased by the government that never reached a single arm, either at home or abroad. While the government secured 61 million doses for a population of just 9 million, the logistical reality saw millions of vials sit in cold storage until they became medical waste. The contracts now reveal why: Moderna strictly prohibited Switzerland from reselling or transferring these vaccines outside its territory, effectively trapping the surplus within Swiss borders until it expired. This massive destruction of taxpayer-funded resources raises urgent questions about procurement strategies that prioritized over-ordering at any cost, leaving the public to foot the bill for a mountain of discarded medicine.
While federal planners miscalculate future costs, the existing Swiss rail network is screaming for attention with a maintenance backlog that has surged to CHF 9.5 billion. The national railway operator (SBB) warns that the infrastructure requires massive, immediate investment just to maintain current safety and reliability standards. The contrast is jarring: while billions are lost to poor planning and pandemic waste, the physical tracks beneath our feet are deteriorating. Auditors highlight that current planning fails to account for legal challenges that block work for years, further inflating the final bill. Switzerland now faces a dual-front financial war—closing the gap on past maintenance while trying to find the billions 'missing' from future project estimates. Without a radical overhaul of how the Federal Office of Transport manages the Rail Infrastructure Fund, the gold standard of Swiss rail is at risk of tarnishing.
The era of 'trust us, we’re the government' is over. The simultaneous exposure of rail miscalculations and vaccine price-gouging marks a turning point for Swiss federal accountability. The transport ministry has been forced to accept all SFAO recommendations, promising to strengthen the 'traceability' of long-term financial planning. Meanwhile, the legal precedent set by the vaccine contract release ensures that the FOPH can no longer hide behind claims of 'national interest' to avoid the Freedom of Information Act. These twin scandals demand a new standard of fiscal discipline in Bern. As Switzerland moves forward, the focus must shift from rapid spending to radical transparency. The Swiss taxpayer is no longer content with being the silent financier of underestimated projects and secret contracts; they are demanding a seat at the table and a clear view of the ledger.